Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Treasury Shares (2022 - 2024)

Zentalis Pharmaceuticals has reported Treasury Shares over the past 3 years, most recently at $7.5 million for Q4 2024.

  • Quarterly results put Treasury Shares at $7.5 million for Q4 2024, up 515.35% from a year ago — trailing twelve months through Dec 2024 was $7.5 million (up 515.35% YoY), and the annual figure for FY2024 was $7.5 million, up 515.35%.
  • Treasury Shares for Q4 2024 was $7.5 million at Zentalis Pharmaceuticals, up from $1.2 million in the prior quarter.
  • Over the last five years, Treasury Shares for ZNTL hit a ceiling of $7.5 million in Q4 2024 and a floor of $125506.0 in Q4 2022.
  • Median Treasury Shares over the past 3 years was $1.2 million (2023), compared with a mean of $2.9 million.
  • Biggest five-year swings in Treasury Shares: soared 871.12% in 2023 and later skyrocketed 515.35% in 2024.
  • Zentalis Pharmaceuticals' Treasury Shares stood at $125506.0 in 2022, then soared by 871.12% to $1.2 million in 2023, then skyrocketed by 515.35% to $7.5 million in 2024.
  • The last three reported values for Treasury Shares were $7.5 million (Q4 2024), $1.2 million (Q4 2023), and $125506.0 (Q4 2022) per Business Quant data.